SCYNEXIS, Inc. Amortization of Debt Discount (Premium)
SCYNEXIS, Inc. (SCYX) reported Amortization of Debt Discount (Premium) of $428.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2019-03-14
- SCYNEXIS, Inc. amortization of debt discount (premium) for the quarter ending 2018-12-31 was $114.00K, a 14.00% increase year-over-year.
- SCYNEXIS, Inc. amortization of debt discount (premium) for the quarter ending 2018-09-30 was $102.00K, a 2.00% increase year-over-year.
- SCYNEXIS, Inc. amortization of debt discount (premium) for the quarter ending 2018-06-30 was $101.00K, a 1.00% increase year-over-year.
- SCYNEXIS, Inc. amortization of debt discount (premium) for the quarter ending 2018-03-31 was $111.00K, a 11.00% increase year-over-year.
- SCYNEXIS, Inc. amortization of debt discount (premium) for fiscal 2018 was $428.00K, a 7.00% increase from fiscal 2017.
- SCYNEXIS, Inc. amortization of debt discount (premium) for fiscal 2017 was $400.00K, a 300.00% increase from fiscal 2016.
- SCYNEXIS, Inc. amortization of debt discount (premium) for fiscal 2016 was $100.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $216.00K derived: sum of 2 quarters · filed 2019-03-14 | $317.00K derived: sum of 3 quarters · filed 2019-03-14 | $428.00K 10-K · filed 2019-03-14 |
| 2018-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $203.00K derived: sum of 2 quarters · filed 2018-11-13 | $314.00K 10-Q · filed 2018-11-13 | $414.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $212.00K 10-Q · filed 2018-08-09 | $312.00K derived: sum of 3 quarters · filed 2019-03-14 | $412.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | $111.00K 10-Q · filed 2018-05-08 | $211.00K derived: sum of 2 quarters · filed 2019-03-14 | $311.00K derived: sum of 3 quarters · filed 2019-03-14 | $411.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $200.00K derived: sum of 2 quarters · filed 2019-03-14 | $300.00K derived: sum of 3 quarters · filed 2019-03-14 | $400.00K 10-K · filed 2019-03-14 |
| 2017-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $200.00K derived: sum of 2 quarters · filed 2018-11-13 | $300.00K 10-Q · filed 2018-11-13 | $400.00K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $200.00K 10-Q · filed 2018-08-09 | $300.00K derived: sum of 3 quarters · filed 2018-08-09 | $300.00K derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $100.00K 10-Q · filed 2018-05-08 | $200.00K derived: sum of 2 quarters · filed 2018-05-08 | $200.00K derived: sum of 3 quarters · filed 2018-05-08 | |
| 2016-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $100.00K derived: sum of 2 quarters · filed 2018-03-13 | $100.00K 10-K · filed 2018-03-13 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |